Compare

Invivyd Inc/$IVVD

1D1W1M3M6MYTD1Y5YMAX

About Invivyd Inc

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Ticker
$IVVD
Sector
Health
Primary listing
NASDAQ
Employees
122

Invivyd Inc Metrics

BasicAdvanced
$124M
-
-$0.42
1.29
-

What the Analysts think about Invivyd Inc

Analyst ratings (Buy, Hold, Sell) for Invivyd Inc stock.
Analyst projections of the future price of Invivyd Inc stock.

Invivyd Inc Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Invivyd Inc Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing Invivyd Inc

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.